Aegon Ltd. New York Registry Shares (AEG)

Total Costs & Expenses

€6.50B

Quarterly · Period ending: · EUR

AEG logo

AEG Total Costs & Expenses

Latest reported€6.50B EUR
AEG Quarterly Total Costs & Expenses · EUR (€877.14M → €6.50B)
High-resolution chart · PNG

AEG total costs & expenses history

Quarterly · EUR. Dates are reporting period ends; fiscal years can differ from calendar years.

Aegon Ltd. New York Registry Shares Total Costs & Expenses — Quarterly (EUR)
Period endingTotal Costs & Expenses (EUR)
6,499,597,829
18,631,064,139
249,000,000
18,709,000,000
153,000,000
153,000,000
157,500,000
3,099,500,000
6,621,000,000
3,357,000,000
21,703,000,000
-3,576,000,000
-22,810,000,000
-9,052,000,000
13,881,000,000
6,395,000,000
16,468,000,000
8,155,000,000
23,425,000,000
13,324,000,000
32,029,000,000
-22,871,000,000
11,404,000,000
11,404,000,000
19,813,500,000
19,813,500,000
237,500,000
181,500,000
8,183,000,000
8,183,000,000
14,321,000,000
11,703,000,000
10,297,000,000
14,366,000,000
8,554,000,000
16,406,000,000
13,554,000,000
10,288,000,000
12,502,000,000
304,000,000
320,000,000
18,515,000,000
13,345,000,000
8,713,000,000
11,003,000,000
9,419,000,000
12,100,000,000
10,945,000,000
4,761,000,000
16,245,000,000
8,821,000,000
12,984,000,000
6,069,000,000
16,349,000,000
13,646,000,000
828,000,000
7,963,000,000
10,057,000,000
11,624,000,000
36,591,000,000
2,952,000,000
15,056,000,000
10,282,000,000
19,351,000,000
14,935,000,000
2,307,000,000
2,443,000,000
-463,000,000
6,217,000,000
390,000,000
42,172,733,760
118,130,880
111,066,000
97,659,900
45,585,864,760
131,833,140
100,887,030
-8,654,258,820
-10,679,400,140
-12,844,552,980
1,558,662,000
-6,617,953,440
-5,622,220,250
-8,057,136,050
1,604,407,360
-6,721,492,400
-6,596,518,100
-6,283,107,900
1,468,185,660
-7,379,013,840
-7,374,969,920
-6,749,984,640
1,640,347,200
-7,926,387,900
-5,603,116,340
-7,693,008,360
1,364,286,000
-7,580,305,220
-6,585,153,800
-6,589,790,600
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.